CoChat
Sign Up
Cited by 696Cancer survivorship and careCancer-related cognitive impairment studiesHealth Systems, Economic Evaluations, Quality of Life

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Esper, Peg, Mo, Fei, Chodak, Gerald, Sinner, Michael, Cella, David, Pienta, Kenneth J.·1997·Urology
DOI 10.1016/s0090-4295(97)00459-7
Open this paper in CoChat — free account

Abstract

Objectives As the incidence of prostate cancer in the United States exceeds 330,000 in 1997, increasingly more men are faced with treatment choices for which there is no clear approach. At every stage of disease, these treatment choices may involve clinically equivalent modalities that differ in side effects and impact upon quality of life (QOL). Comprehensive, yet efficient, questionnaires are needed to measure QOL in patients with prostate cancer.Methods Developed as a disease-specific adjunct to the Functional Assessment of Cancer Therapy (FACT) measurement system, a 12-item prostate cancer subscale (PCS) was developed and tested in three independent samples: a subscale development sample (n = 43), validity sample 1 (n = 34), and validity sample 2 (n = 96). The 12 items ask about symptoms and problems specific to prostate cancer. These questions are added to the general (FACT-G) instrument, thereby comprising a 47-item questionnaire.Results Internal consistency of the PCS ranged from 0.65 to 0.69, with coefficients for FACT-G subscales and aggregated scores ranging from 0.61 to 0.90. Concurrent validity was confirmed by the ability to discriminate patients by disease stage, performance status, and baseline prostate-specific antigen (PSA) level. Sensitivity to change in performance status and PSA score over a 2-month period suggested that some subscales of the FACT-Prostate (P) (including the PCS) are sensitive to meaningful clinical change.Conclusions Our findings support use of the FACT-P as a meaningful component of QOL evaluation in men undergoing therapy for prostate cancer.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0090-4295(97)00459-7

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 22 references

Research works printed but not linked: 2

  1. da Silva, 1993, Quality of life in patients with prostatic cancer. A feasibility study, Cancer, 71, 1138, 10.1002/1097-0142(19930201)71:3+<1138::AID-CNCR2820711436>3.0.CO;2-7 · DOI
  2. Esper, 1995, FACT-P: a new instrument for quality of life evaluation in prostate cancer (abstract), J Urol, 153

Cited by

Sorted by citations

See all 696

Related

Metadata

Authors
Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J.
Affiliations
Rush University Medical Center (US)
Corresponding author
Esper, Peg
ORCID
Venue
Urology
Publisher
Elsevier BV
Published
1997-12
Volume
50
Issue
6
Pages
920-928
ISSN
0090-4295 (ISSN-L)
DOI
10.1016/s0090-4295(97)00459-7
OpenAlex
W2004909463
Cited by
696
References
22
Citations by year
2026: 18 · 2025: 22 · 2024: 34 · 2023: 25 · 2022: 45 · 2021: 34 · 2020: 20 · 2019: 31 · 2018: 35 · 2017: 29 · 2016: 33 · 2015: 30 · 2014: 28 · 2013: 31 · 2012: 27
FWCI
4.00
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Urology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
prostate cancer, quality of life, Functional Assessment of Cancer Therapy, questionnaire development, concurrent validity, internal consistency, sensitivity to change, prostate-specific antigen, performance status, disease stage
MeSH terms
Aged, Aged, 80 and over, Chicago, Humans, Male, Michigan, Middle Aged, Prostatic Neoplasms, Quality of Life, Surveys and Questionnaires, Sensitivity and Specificity, Reproducibility of Results

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review